Free Trial

Vera Therapeutics Q4 2023 Earnings Report

Vera Therapeutics logo
$42.19 +0.09 (+0.21%)
As of 01/8/2025 04:00 PM Eastern

Vera Therapeutics EPS Results

Actual EPS
-$0.58
Consensus EPS
-$0.53
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

Vera Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vera Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A

Vera Therapeutics Earnings Headlines

Combine the QQQ, IWM and SPY in one trade
If you’ve been investing in the major indexes for the last 20 years, you may need a new strategy. Because the Dow Jones has returned just 349%... The Russell 2000 has returned just 397%... And the S&P 500 has returned just 450%. And although I can’t guarantee results or against losses… I want to tell you about my “2-Click Trade” that has encapsulated more than the return of ALL THREE OF THOSE INDEXES COMBINED… Plus, it targets multiple overnight payouts in a month with 84.3% accuracy! While I cannot promise future returns or against losses…
Promising Developments in VYNE Therapeutics’ VYN202 Support Buy Rating
Carisma Therapeutics (CARM) Receives a Hold from Evercore ISI
See More Vera Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vera Therapeutics and other key companies, straight to your email.

About Vera Therapeutics

Vera Therapeutics (NASDAQ:VERA), a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

View Vera Therapeutics Profile

More Earnings Resources from MarketBeat